Skip to main content
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd — Investor Relations & Filings

Ticker · TLSA ISIN · BMG889121031 LEI · 984500769407C5E46F42 US Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2022-03-02 Regulatory Filings
Country BM Bermuda
Listing US TLSA

About Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com/

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Tiziana Life Sciences Ltd., reporting a deficiency notice from Nasdaq regarding the company's stock price falling below the minimum bid price required for continued listing. The document discusses the compliance period and potential delisting but does not contain financial statements or detailed financial data. It is a regulatory announcement about listing compliance and potential delisting, not a full report or financial filing. The document length is 4379 characters, which is relatively short and primarily an announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Delisting Announcement (DLST) because it is a notice of deficiency and potential future delisting, not an official delisting notice.
2022-03-02 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Form F-3 Registration Statement under the Securities Act of 1933. It is a correspondence related to a registration statement filing, not the registration statement itself or a financial report. The document length is short (1234 characters), and it is a formal request for regulatory processing rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2022-03-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a news service announcement about a specific scientific development by the company, Tiziana Life Sciences LTD. The document is short (2847 characters) and primarily serves to furnish information rather than provide comprehensive financial data or detailed reports. It does not contain financial statements or detailed management discussion. The Form 6-K is typically used for current reports and announcements by foreign private issuers and is classified under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2022-03-01 English
AMENDMENT NO. 2 TO FORM F-3
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 2 to Form F-3, which is a registration statement filed with the U.S. Securities and Exchange Commission under the Securities Act of 1933. It is a prospectus related to the offering of securities (common shares, warrants, units) by Tiziana Life Sciences Ltd. The document includes detailed information about the securities offering, risk factors, capitalization, use of proceeds, and other related disclosures typical of a registration statement for capital raising. This type of filing is best classified under Capital/Financing Update (CAP) because it pertains to the registration and offering of securities, which is a capital raising activity. It is not an annual report, earnings release, or other financial report, nor is it a proxy, voting result, or management change announcement. The document length (15,000 characters) and content confirm it is a substantive filing, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2022-02-25 English
AMENDMENT NO. 1 TO FORM 6-K
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 1 to Form 6-K filed by Tiziana Life Sciences Ltd. It references furnishing interim results for the six months ended June 30, 2021, which were not included in the original Form 6-K. The document includes an explanatory note and a Regulatory News Service (RNS) announcement as an exhibit. The length is 3166 characters, which is relatively short and the document mainly serves to amend a previous filing by providing the interim financial results that were missing. It does not contain the full interim report itself but rather furnishes it as an amendment and includes an RNS announcement. According to the rules, Form 6-K filings and amendments that provide regulatory announcements or furnish information without containing full financial statements or substantive financial data are classified as Regulatory Filings (RNS). Therefore, this document is best classified as a Regulatory Filing (RNS).
2022-02-22 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 100% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains an announcement about the CEO presenting at a conference and includes a news service announcement as an exhibit. The document is relatively short (2910 characters) and does not contain financial statements or detailed financial data. It is primarily an announcement of an event rather than a full report or detailed financial disclosure. According to the rules, such documents that are announcements or furnish information without substantive financial data or detailed reports should be classified as Regulatory Filings (RNS).
2022-02-10 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.